US Drug Prices Face Seismic Shift: Pharma Giants Negotiate Deep Cuts
December 20, 2025, 4:38 pm
Location: United States, New Jersey, Lawrence
Employees: 10001+
Founded date: 1858
Location: United States, California, Foster City
Employees: 10001+
Founded date: 1987
Total raised: $304M
Location: United States, Massachusetts, Cambridge
Employees: 10001+
Founded date: 1981
Total raised: $1.1B
The American healthcare landscape is transforming. US drug prices, long the world's highest, face unprecedented pressure. President Trump drove an aggressive campaign to lower prescription costs. His administration pushed the Most Favored Nation (MFN) policy. This initiative links US drug prices to lower international averages. It targets global disparities. Companies not complying faced stiff tariff threats. Fourteen major pharmaceutical firms, both US and European, have now struck deals. These agreements promise significant price reductions. They aim to boost drug affordability for millions of Americans.
The United States has long been a unique market. Drug prices here dwarf those in other developed nations. Branded medications often cost three to four times more. This high-price environment fueled pharma's profitability. It also burdened American patients and taxpayers. The US market became vital for global biopharmaceutical companies. Many European firms generate a majority of their total sales from America.
President Trump’s administration targeted this disparity. It launched a forceful campaign. The MFN drug pricing policy became a cornerstone. This policy mandates US prices match the lowest rates paid by other wealthy countries. An executive order solidified this intent. The goal was clear: end "global freeloading" on American consumers.
Pressure mounted quickly. Trump sent letters to 17 top drugmakers. He demanded immediate price reductions. The administration also threatened severe financial penalties. Triple-digit tariffs loomed for companies. These tariffs targeted firms unwilling to invest in US manufacturing. They also applied to those failing to lower prices. This created a powerful incentive for compliance.
Many pharmaceutical giants responded. Fourteen companies entered into agreements. These include Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, EMD Serono, Gilead Sciences, GSK, Merck, Novartis, Novo Nordisk, Pfizer, Roche’s Genentech, and Sanofi. These deals mark a significant shift. They represent a new era of direct government negotiation.
The negotiated terms are extensive. They include several key components. Companies agreed to reduce Medicaid drug prices. These prices will now align with MFN levels. New medications will also adopt MFN pricing across all markets. This covers commercial, cash pay, Medicare, and Medicaid patients. These changes promise broad impact.
Patient access is another focus. Drugmakers agreed to list popular medications on TrumpRx. This new direct-to-consumer platform launches in January. Some companies expanded existing direct-to-patient programs. Gilead will offer its hepatitis C treatment, Epclusa, at a discount. Sanofi pledges nearly 70% off for certain infection and cardiovascular medicines. Merck will discount three diabetes medications by roughly 70% for cash-paying patients. Amgen offers significant discounts on migraine and autoimmune treatments. These initiatives aim to put affordable drugs directly into patients' hands.
The agreements go beyond pricing. Several firms committed to US manufacturing. They will receive a three-year grace period from tariffs. This encourages domestic production. It strengthens the US supply chain. Some companies also pledged vital donations. Merck, GSK, and Bristol Myers Squibb will donate active pharmaceutical ingredients. These will bolster a national reserve. They ensure access to critical medicines like antibiotics and blood thinners during emergencies.
One remarkable commitment stands out. Bristol Myers Squibb will provide Eliquis free to Medicaid. Eliquis is a blockbuster blood thinner. It is a top-prescribed drug. It is also one of Medicaid’s most widely used medicines. This donation signifies a move toward health equity. It shows drugmakers can balance profits with public good.
European pharmaceutical companies face particular exposure. The US market is their most significant revenue source. Five of the ten largest biopharmaceutical companies in the Stoxx 600 health index get majority sales from the US. Argenx is highly exposed, with 85% of sales from the US. AstraZeneca, with 42% of sales from the US, aims for further growth. Roche and Novartis, Europe's largest by market value, also negotiated deals. Germany's Merck KGaA and Bayer have less US exposure. Their diversified businesses cushion the impact. These negotiations force strategic re-evaluations across the Atlantic.
The full impact of these deals is yet to be seen. Analysts suggest some initial agreements might be "more benign" than perceived. However, the sheer volume of commitments is notable. Lower prices will help state budgets funding Medicaid programs. Uninsured patients, previously without leverage, will also benefit. The long-term effects on pharmaceutical research and development remain uncertain. Yet, the push for affordability is undeniable.
These reforms signify a monumental shift. They reshape the pharmaceutical industry's relationship with the US government. They redefine drug pricing practices. The focus remains clear: make essential medicines more affordable for all Americans. This unprecedented effort sets a new precedent for healthcare negotiations. It prioritizes patient access and cost control.
The United States has long been a unique market. Drug prices here dwarf those in other developed nations. Branded medications often cost three to four times more. This high-price environment fueled pharma's profitability. It also burdened American patients and taxpayers. The US market became vital for global biopharmaceutical companies. Many European firms generate a majority of their total sales from America.
President Trump’s administration targeted this disparity. It launched a forceful campaign. The MFN drug pricing policy became a cornerstone. This policy mandates US prices match the lowest rates paid by other wealthy countries. An executive order solidified this intent. The goal was clear: end "global freeloading" on American consumers.
Pressure mounted quickly. Trump sent letters to 17 top drugmakers. He demanded immediate price reductions. The administration also threatened severe financial penalties. Triple-digit tariffs loomed for companies. These tariffs targeted firms unwilling to invest in US manufacturing. They also applied to those failing to lower prices. This created a powerful incentive for compliance.
Many pharmaceutical giants responded. Fourteen companies entered into agreements. These include Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, EMD Serono, Gilead Sciences, GSK, Merck, Novartis, Novo Nordisk, Pfizer, Roche’s Genentech, and Sanofi. These deals mark a significant shift. They represent a new era of direct government negotiation.
The negotiated terms are extensive. They include several key components. Companies agreed to reduce Medicaid drug prices. These prices will now align with MFN levels. New medications will also adopt MFN pricing across all markets. This covers commercial, cash pay, Medicare, and Medicaid patients. These changes promise broad impact.
Patient access is another focus. Drugmakers agreed to list popular medications on TrumpRx. This new direct-to-consumer platform launches in January. Some companies expanded existing direct-to-patient programs. Gilead will offer its hepatitis C treatment, Epclusa, at a discount. Sanofi pledges nearly 70% off for certain infection and cardiovascular medicines. Merck will discount three diabetes medications by roughly 70% for cash-paying patients. Amgen offers significant discounts on migraine and autoimmune treatments. These initiatives aim to put affordable drugs directly into patients' hands.
The agreements go beyond pricing. Several firms committed to US manufacturing. They will receive a three-year grace period from tariffs. This encourages domestic production. It strengthens the US supply chain. Some companies also pledged vital donations. Merck, GSK, and Bristol Myers Squibb will donate active pharmaceutical ingredients. These will bolster a national reserve. They ensure access to critical medicines like antibiotics and blood thinners during emergencies.
One remarkable commitment stands out. Bristol Myers Squibb will provide Eliquis free to Medicaid. Eliquis is a blockbuster blood thinner. It is a top-prescribed drug. It is also one of Medicaid’s most widely used medicines. This donation signifies a move toward health equity. It shows drugmakers can balance profits with public good.
European pharmaceutical companies face particular exposure. The US market is their most significant revenue source. Five of the ten largest biopharmaceutical companies in the Stoxx 600 health index get majority sales from the US. Argenx is highly exposed, with 85% of sales from the US. AstraZeneca, with 42% of sales from the US, aims for further growth. Roche and Novartis, Europe's largest by market value, also negotiated deals. Germany's Merck KGaA and Bayer have less US exposure. Their diversified businesses cushion the impact. These negotiations force strategic re-evaluations across the Atlantic.
The full impact of these deals is yet to be seen. Analysts suggest some initial agreements might be "more benign" than perceived. However, the sheer volume of commitments is notable. Lower prices will help state budgets funding Medicaid programs. Uninsured patients, previously without leverage, will also benefit. The long-term effects on pharmaceutical research and development remain uncertain. Yet, the push for affordability is undeniable.
These reforms signify a monumental shift. They reshape the pharmaceutical industry's relationship with the US government. They redefine drug pricing practices. The focus remains clear: make essential medicines more affordable for all Americans. This unprecedented effort sets a new precedent for healthcare negotiations. It prioritizes patient access and cost control.